Tower Research Capital (TRC)’s ProShares Ultra CRCL CRCA Stock Holding History

Tower Research Capital (TRC)’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9	Closed	-$372	–	5803
2026 Q1	$372	Buy	+9	New	+$374	﹤0.01%	4893

Other funds holding CRCA

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

Tower Research Capital (TRC)'s CRCA Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of ProShares Ultra CRCL (CRCA) in Q2 2026, closing a stake of 9 shares — an estimated $372 sold.

Tower Research Capital (TRC) first reported a position in CRCA in Q1 2026 and held it in 1 quarter. The position peaked at $372 in Q1 2026. 8 funds tracked by Wall St. Rank hold CRCA as of Q2 2026.

Tower Research Capital (TRC) reported no remaining ProShares Ultra CRCL position as of Q2 2026 after selling out during the quarter.
Tower Research Capital (TRC) sold 9 ProShares Ultra CRCL shares in Q2 2026, an estimated $372.
Tower Research Capital (TRC) first reported a position in ProShares Ultra CRCL in Q1 2026 and held it in 1 quarter.
Tower Research Capital (TRC)'s ProShares Ultra CRCL position peaked at $372 in Q1 2026.
8 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.